Updated: Reddy's Follows Endo On US Kuvan Launch
Sapropterin Market Worth Roughly $500m
Executive Summary
Under the terms of a patent-litigation settlement from April 2017, Endo’s Par subsidiary has launched the first US generic versions of BioMarin’s Kuvan (sapropterin) tablet and powder formulations. Rival ANDA sponsor Dr Reddy’s has followed suit on the tablet formulation.
You may also be interested in...
Endo Aims To Stabilize Generics Unit In 2021
Endo will focus on restructuring initiatives and new launches in 2021 to stabilize its generics business, after the company reported a 20% drop in generics sales for the fourth quarter of 2020, with full-year sales down by more than a tenth.
Five New EU Filings Leave Starting Blocks at EMA
There is one orphan drug among the five new marketing authorization applications that the European Medicines Agency has under review. All five drugs will be reviewed under standard review timelines.
Endo’s Par Opts For Authorized Generic As It Debuts Lubiprostone In US
Endo’s Par has introduced the first generic version of Mallinckrodt’s chronic idiopathic constipation medicine Amitiza, realizing the terms of a settlement agreement announced more than six years ago.